Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation

Alexandratou, E; Kyriazi, M; Trebst, T; Grafe, S; Yova, D

dc.contributor.author	Alexandratou, E	en
dc.contributor.author	Kyriazi, M	en
dc.contributor.author	Trebst, T	en
dc.contributor.author	Grafe, S	en
dc.contributor.author	Yova, D	en
dc.date.accessioned	2014-03-01T02:51:09Z
dc.date.available	2014-03-01T02:51:09Z
dc.date.issued	2007	en
dc.identifier.issn	16057422	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/35408
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-36248970198&partnerID=40&md5=0e76b38e03107f63ad7b44b47c3b08df	en
dc.subject	Liposomal formulation	en
dc.subject	mTHPC	en
dc.subject	Non melanoma skin cancer	en
dc.subject	Photodynamic therapy	en
dc.subject	Topical application	en
dc.subject.other	Diseases	en
dc.subject.other	Liposomes	en
dc.subject.other	Oncology	en
dc.subject.other	Photosensitizers	en
dc.subject.other	Skin	en
dc.subject.other	Energy doses	en
dc.subject.other	Liposomal formulations	en
dc.subject.other	Melanoma skin carcinomas	en
dc.subject.other	Photodynamic efficacy	en
dc.subject.other	Topical applications	en
dc.subject.other	Photodynamic therapy	en
dc.title	Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation	en
heal.type	conferenceItem	en
heal.identifier.secondary	66320V	en
heal.publicationDate	2007	en
heal.abstract	Photodynamic therapy (PDT) has been used in the treatment of various skin diseases including non melanoma skin carcinomas (NMSC). However, until now there are no publications concerning the efficacy of PDT after topical application of mTHPC. Although topical photosensitizer application presents many advantages over systemic drug administration, ALA-induced protoporphyrin IX is the only sensitizer topically used so far. In the present study photodynamic efficacy of the highly potent sensitizer meso-tetra(hydroxyphenyl)chlorin (mTHPC), supplied in a novel liposome formulation is investigated after topical application in hairless SKH-HR1 mice, bearing non melanoma skin carcinomas. The drug was applied topically for drug - light interval of 4 hours. The fluence rates were 100 and 50 mW/cm2 and two total energy doses, 10 J/cm2 and 100 J/cm2 were studied in groups of 5 animals. Three PDT sessions were performed in each animal, once every 7 days. The final evaluation of PDT effects was performed 14 days after the 3rd PDT treatment by measuring the geometrical characteristics of tumors. The groups treated with 100 mW/cm2 presented a higher complete tumor remission than the group of 50 mW/cm2 but an unusual high mortality. In the group of 50 mW/cm2 and 100 J/cm2, although the complete tumor remission percentage is poor, the tumor growth rate was decreased. No lesion, papilloma, or tumor was observed in the treated area even six months after tumor remission. Furthermore tumours up to 7 mm were achieved to be treated, indicating that this novel mTHPC formulation could be used for deeper and not only superficial carcinomas or lesions. © 2007 SPIE-OSA.	en
heal.journalName	Progress in Biomedical Optics and Imaging - Proceedings of SPIE	en
dc.identifier.volume	6632	en